Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Direct
133 Pages - GMD19944
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 9, 2, 22, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gouty Arthritis (Gout) - Overview
Gouty Arthritis (Gout) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gouty Arthritis (Gout) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
Gouty Arthritis (Gout) - Drug Profiles
Gouty Arthritis (Gout) - Dormant Projects
Gouty Arthritis (Gout) - Discontinued Products
Gouty Arthritis (Gout) - Product Development Milestones
Featured News & Press Releases
Aug 09, 2022: Arthrosi completes AR882 renal impairment study
Aug 03, 2022: LG Chem enters final stage of clinical development for new gout drug
Jul 19, 2022: Allena pharmaceuticals announces completion of enrollment of cohorts A and B of ALLN-346 phase 2a study 202 in patients with Gout and stages 2 and 3 chronic kidney disease
Jun 16, 2022: Atom Bioscience to update clinical development of new drug to treat gout at BIO International Convention, June 13 - 16, 2022, San Diego, CA
Jun 13, 2022: Selecta Biosciences announces partnership advancements and clinical trial updates
Jun 02, 2022: Dyve Biosciences announces phase 2 TARGETS study of DYV702 for pain associated with acute gout flares showcased in podium presentation at 2022 EULAR congress
May 31, 2022: Fortress Biotech announces first patient dosed in phase 1 clinical trial evaluating dotinurad for the treatment of gout in the United States
Mar 21, 2022: Atom Bioscience announces positive phase 2a results for investigational new drug to treat chronic gout
Mar 15, 2022: The Phase I clinical trial of Eusen Jianheng's new gout drug UA007 was successfully completed
Dec 14, 2021: Arthrosi Therapeutics announces patient enrollment in global phase 2b study of AR882
Dec 02, 2021: Sobi and Selecta Biosciences complete enrolment for gout therapy trial
Nov 15, 2021: Dyve Biosciences hosting key opinion leader webinar on Gout and DYV702
Nov 08, 2021: Shanghai Fosun Pharmaceutical (Group) announcement in relation to the approval for Clinical Trial regarding Investigational New Drug of a subsidiary
Nov 03, 2021: Allena Pharmaceuticals receives Fast Track Designation from FDA for the Development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease
Nov 02, 2021: Arthrosi presents AR882 posters at ACR 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gouty Arthritis (Gout), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gouty Arthritis (Gout) - Dormant Projects, 2022
Gouty Arthritis (Gout) - Dormant Projects, 2022 (Contd..1)
Gouty Arthritis (Gout) - Dormant Projects, 2022 (Contd..2)
Gouty Arthritis (Gout) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Gouty Arthritis (Gout), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

[email protected]
+1 212 564 2838

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

[email protected]
+1 212 564 2838

Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838